New evidence reported in the August issue of Cell Stem Cell, a publication of Cell Press, offers a novel perspective on how the HIV/AIDS virus leads to learning and memory deficits, a condition known as HIV-associated dementia.
The 2006 estimates released recently by the Indian National AIDS Control Organisation, supported by UNAIDS and WHO, indicate that an estimated 2 million to 3.1 million people are living with HIV in the India.
Few older women were interested in being tested for the virus that causes AIDS despite having significant risk factors for lifetime exposure, according to a study published in the July/August edition of the Journal of Women?s Health.
GlaxoSmithKline GSK announced that it has given consent to Toronto-based drug company Apotex to use two of its patented antiretroviral drugs, lamivudine and zidovudine, to manufacture Apo-triAvir — a fixed-dose combination of the two drugs and the antiretroviral nevirapine — for the treatment of HIV/AIDS in Rwanda.
Abbott has received a supplemental Premarket Approval from the U.S. Food and Drug Administration for its recently introduced RealTime HIV-1 viral load test.
US’ Largest HIV/AIDS Healthcare Provider Says Pfizer?s Commercials Recklessly Promote Viagra as a ?Party Drug? by Encouraging its Recreational Use, But Exclude STD and HIV Transmission Warning from Spoken List of Potential Medical Risks
On the heels of the fourth International AIDS Society?s Conference on HIV Pathogenesis, Treatment and Prevention, which took place in Sydney in late July, AIDS Healthcare Foundation (AHF) welcomed yesterday?s news that the FDA has approved Pfizer Inc.?s new AIDS salvage therapy, Selzentry (maraviroc), a different class of new antiretroviral AIDS drug which had been discussed and presented at the IAS conference.
A significant rise in the incidents of HIV among women trafficked via India’s International borders is proving to be an important factor in spreading the deadly virus to its “lower-prevalence neighbours”, according to a study.
As part of its broad commitment to improving access to medicines, GlaxoSmithKline announced it has given consent through Canada?s Access to Medicines Regime to enable a Canadian company (Apotex) to manufacture a generic fixed dose combination (FDC) antiretroviral (ARV), containing two molecules over which GSK has patent rights (zidovudine and lamivudine) for the treatment of HIV/AIDS in Rwanda.
The U.S. Food and Drug Administration (FDA) approved maraviroc, an antiretroviral drug for use in adult HIV patients. Maraviroc, sold under the trade name Selzentry, is the first in a new class of drugs designed to slow the advancement of HIV and received priority review by the FDA.